ADC Intelligence Platform
The competitive intelligence feed for the ADC drug pipeline.
BiotechSentry turns clinical-trial registries, regulatory filings, and global patent data into ranked, ADC-specific intelligence events — automatically, in hours, not weeks.
The problem
Analysts are drowning in data and starving for signal.
ADC is the most competitive oncology class of the decade — and the teams responsible for tracking it are still working across dozens of sources by hand. The data is all public. Extracting it fast, resolving the entities, and ranking what matters is the hard part.
ADC programs in active development — more than any other oncology modality.
Deal pressure has CI teams under board-level scrutiny to never miss a move.
Spent on manual data collection — leaving only a fraction for real analysis.
How it works
From raw filing to ranked alert — continuously.
A purpose-built pipeline that watches the public record around the clock and surfaces only what an ADC analyst needs to see.
Live data connectors
Clinical-trial registries, regulatory filings, and global patent data, polled continuously and stored with full provenance.
ADC-specific filter
Payload, linker, and target heuristics score every document, so only ADC-relevant records enter the knowledge graph.
Knowledge graph
Companies, assets, targets, indications, trials, and patents are linked into one navigable, live graph.
Intelligence events
State changes become events — scored by impact and risk, and delivered ranked to the right analyst.
The product
Every move in the ADC race, in one place.
Navigate the whole competitive set.
Jump from a company to an asset, to its target, to every active trial and pending approval in the space — in a couple of clicks.
- →A ranked “New this week” feed so the most consequential changes rise to the top.
- →Entity detail pages with trial timelines, approval history, and patent portfolios.
- →Impact & risk scoring on every event, tuned to ADC development.
- →Watchlists & alerts delivered the moment something moves.
Why now
The ADC window is open — briefly.
Four forces converged to make a focused intelligence layer both necessary and finally buildable.
An approval pipeline at all-time highs
A wave of new ADC approvals and submissions means more state changes to track than any team can follow by hand.
Every major pharma is acquiring or partnering
Missing a competitor move now carries a strategic cost measured in billions — CI is no longer a back-office function.
The raw data is finally programmatic
Public registries and filings are now accessible by API. The pipes exist — the intelligence layer on top did not.
Extraction is a fraction of its former cost
A small, focused team can now build what used to require an army of analysts and rule-based systems.
Who it's for
Built for the people who can't afford to miss.
Stop collecting. Start analyzing.
Replace the manual surveillance workflow with a continuous, ranked feed — and give your analysts their time back for judgment.
See the change before the meeting.
Catch trial status changes, approvals, and patent grants days earlier, with the full competitive context already attached.
Read the landscape in minutes.
Navigate the entire ADC graph — assets, targets, trials, and deal-relevant signals — without commissioning a consulting project.
FAQ
Questions, answered.
What does BiotechSentry actually do?+
How fast is the data?+
How is this different from the tools we already use?+
Is it only for ADCs?+
What does it cost?+
How do we get started?+
Request a demo
See your competitive set, live.
Tell us a little about your team and we'll set up a walkthrough on your real ADC landscape — plus early access to the platform.
Prefer to start small? Subscribe to the free weekly ADC Intelligence Report →